In humans, evidence of enhanced IL-6 serum levels has been detected in both NAFL and NASH patients [131,149], as well as increased IL-6 hepatic expression in NASH which seemed to correlate with the severity of the disease (Table 1) [150]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatohepatitis.